The weight loss drug battle just got a lot less competitive. Over the past two days, Novo Nordisk A/S (NVO) has watched its stock crater roughly 18% after delivering disappointing guidance for fiscal 2026. Meanwhile, Eli Lilly and Co. (LLY) investors are celebrating blockbuster fourth quarter earnings and an optimistic outlook that suggests the pharmaceutical giant is pulling decisively ahead.

Novo's Troubling 2026 Outlook

Here's where things get uncomfortable for Novo Nordisk. The company expects 2026 sales growth—excluding $4.2 billion in revenue from the reversal of 340B provisions—to decline between 5% and 13% at constant exchange rates. That's not a typo. They're forecasting negative growth.

The culprits? Lower realized prices driven by the "Most Favoured Nations" agreement in the U.S., patent expiry of the semaglutide molecule in certain international markets, and intensifying competition. It's the perfect storm of pricing pressure and market share erosion.

For context, Novo Nordisk's sales increased 10% in 2025 to 309.06 billion Danish kroner at constant exchange rates, with operating profit climbing 6% to 127.66 billion Danish kroner. Those numbers came in below the company's earlier guidance of 8% to 11% sales growth and 4% to 7% operating profit growth.

Lilly's Victory Lap

Eli Lilly, by contrast, is projecting fiscal 2026 adjusted earnings between $33.50 and $35 per share, beating the consensus estimate of $33.23. More impressively, the company expects sales of $80 billion to $83 billion—well ahead of Wall Street's $77.62 billion estimate. The midpoint represents 25% growth, a stark contrast to Novo's projected decline.

Weight Loss Drug Revenue: The Numbers Don't Lie

The revenue comparison tells the whole story. Novo Nordisk's Ozempic sales increased just 1% to 31.83 billion Danish kroner (approximately $5.03 billion), while Wegovy sales rose 17% to 21.86 billion Danish kroner (around $3.46 billion).

Eli Lilly's performance? Mounjaro revenue more than doubled to $7.4 billion. U.S. Zepbound revenue surged 122% to $4.2 billion. Those aren't incremental gains—they're market share conquests.

The Bigger Picture: Pipeline Matters

Over the past year, Novo Nordisk stock has plummeted roughly 42%, while Eli Lilly shares have climbed about 34%. The divergence isn't just about current sales—it's about strategic positioning.

Novo Nordisk's pipeline concentrates primarily on insulin products, heart disease medications, and weight loss drugs. It's a focused approach, but also potentially limiting.

Eli Lilly's pipeline? Much broader. The company has drugs in development for cancer, weight loss, Alzheimer's disease, arthritis, psoriasis, allergic rhinitis, gastric disorders, and skin diseases. That diversification provides both revenue stability and multiple growth avenues.

The Marketing Battle

Novo Nordisk sharply increased its U.S. advertising spend on Wegovy and Ozempic in 2025, actually outpacing Eli Lilly as competition for market share intensified. Wegovy, approved in the U.S. in mid-2021, represented a major advancement in obesity treatment at the time.

But throwing advertising dollars at the problem hasn't stopped the momentum shift. Novo has struggled to keep pace with Lilly's Zepbound, which surpassed Wegovy in weekly new prescriptions this year. When your competitor is winning despite spending less on marketing, that's a product superiority problem, not an awareness problem.

Price Action: Novo Nordisk shares were down 5.85% at $47.35 and Eli Lilly shares were up 9.56% at $1,099.38 at the time of publication on Wednesday.